Outlook to conduct another trial for wet AMD drug; Cara strikes new royalty deal
Outlook to conduct another trial for eye drug after rejection: Outlook Therapeutics announced Thursday that the FDA wants an additional study assessing bevacizumab in wet age-related macular degeneration. The company had received a complete response letter in August, with the regulator citing “several CMC issues, open observations from pre-approval manufacturing inspections and a lack of substantial evidence.” It now plans to resubmit the application in late 2024, aiming for an approval in mid-2025.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.